# ML-007C-MA PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/ml-007c-ma

> The next catalyst for ML-007C-MA, sponsored by MapLight Therapeutics, Inc. (MPLT), is its primary completion, December 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | ML-007C-MA |
| Codes | ML-007C-MA, ML-007C |
| Sponsor | MapLight Therapeutics, Inc. (MPLT) https://sec-api.dev/companies/mplt/catalysts |
| Indications | [Psychosis Associated With Alzheimer's Disease](https://sec-api.dev/indications/psychosis-associated-with-alzheimer-s-disease), [Schizophrenia](https://sec-api.dev/indications/schizophrenia) |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### December 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Psychosis Associated With Alzheimer's Disease.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06887192 (A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-12 (ESTIMATED); Lead Sponsor MapLight Therapeutics." https://clinicaltrials.gov/study/NCT06887192

### Dec 2027 to Mar 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Psychosis Associated With Alzheimer's Disease.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06887192 (A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-12 (ESTIMATED); Lead Sponsor MapLight Therapeutics." https://clinicaltrials.gov/study/NCT06887192

### March 2029: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Psychosis Associated With Alzheimer's Disease.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07459660 (An Open-Label Study of ML-007C-MA in Adults With Alzheimer's Disease Psychosis): Overall Status ENROLLING_BY_INVITATION; Phase PHASE2; Primary Completion 2029-03 (ESTIMATED); Lead Sponsor MapLight Therapeutics." https://clinicaltrials.gov/study/NCT07459660

### Mar to Jun 2029: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Psychosis Associated With Alzheimer's Disease.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07459660 (An Open-Label Study of ML-007C-MA in Adults With Alzheimer's Disease Psychosis): Overall Status ENROLLING_BY_INVITATION; Phase PHASE2; Primary Completion 2029-03 (ESTIMATED); Lead Sponsor MapLight Therapeutics." https://clinicaltrials.gov/study/NCT07459660

### February 2030: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Schizophrenia.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07459647 (A Long-Term Open-Label Study of ML-007C-MA in Adults With Schizophrenia): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2030-02 (ESTIMATED); Lead Sponsor MapLight Therapeutics." https://clinicaltrials.gov/study/NCT07459647

### Feb to May 2030: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Schizophrenia.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07459647 (A Long-Term Open-Label Study of ML-007C-MA in Adults With Schizophrenia): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2030-02 (ESTIMATED); Lead Sponsor MapLight Therapeutics." https://clinicaltrials.gov/study/NCT07459647

## Same indication

- [ALTO-101](https://sec-api.dev/pdufa/alto-101) (ANRO)
- [Anavex3-71 oral capsules](https://sec-api.dev/pdufa/anavex3-71-oral) (AVXL)
- [Brenipatide](https://sec-api.dev/pdufa/brenipatide) (LLY)
- [Cariprazine flexible dose](https://sec-api.dev/pdufa/cariprazine-flexible-dose) (ABBV)
- [Emraclidine](https://sec-api.dev/pdufa/emraclidine) (ABBV)
- [GXV813](https://sec-api.dev/pdufa/gxv813) (NVS)
- [Fanapt® (iloperidone)](https://sec-api.dev/pdufa/iloperidone) (VNDA)
- [Karxt](https://sec-api.dev/pdufa/karxt) (BMY)
- [Lb-102 (50 mg tablet)](https://sec-api.dev/pdufa/lb-102) (LBRX)
- [Ml-007c-ma bid](https://sec-api.dev/pdufa/ml-007c-ma-bid) (MPLT)
- [NBI-1117568](https://sec-api.dev/pdufa/nbi-1117568) (NBIX)
- [NBI-1117570](https://sec-api.dev/pdufa/nbi-1117570) (NBIX)
- [Olz/sam](https://sec-api.dev/pdufa/olz-sam) (ALKS)
- [BRIUMVI® (ublituximab)](https://sec-api.dev/pdufa/ublituximab) (TGTX)
- [Xanomeline and trospium chloride capsules](https://sec-api.dev/pdufa/xanomeline-and-trospium) (BMY)
- [Xanomeline/trospium chloride](https://sec-api.dev/pdufa/xanomeline-trospium) (BMY)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/ml-007c-ma.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "ML-007C-MA PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/ml-007c-ma

```bibtex
@misc{secapidev_pdufa_ml_007c_ma_20261116,
  title        = {ML-007C-MA PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/ml-007c-ma}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_ml_007c_ma_20261116","title":"ML-007C-MA PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/ml-007c-ma","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
